BRD4-targeted therapy ABBV-744 clinical data No Further a Mystery
These side effects ended up notably milder compared to an inhibitor of equally bromodomains. An in depth molecular analysis also discovered that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen TaylorFor all circulation cytometry experiments, 10,000 cells per replicate were analyzed, and 3 rep